Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer—an international, multicentre, real-world analysis

Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer—an international, multicentre, real-world analysis

Background: This study explores the potential benefits of neoadjuvant chemotherapy in borderline resectable (BR) pancreatic adenocarcinoma. Despite neoadjuvant treatment (NAT) increasingly being utilised, uncertainty remains as to the optimal approach. Patients and methods: This study assessed clini...

Full description

Saved in:
Bibliographic Details
Main Authors: S. Banks, W. Hong, K. Degeling, J. Shapiro, B. Thomson, H.S. Ko, S. Ananda, A. Jalali, Y.H. To, B. Loveday, S.-A. McLachlan, B. Knowles, A. Fox, M. Michael, R. Wong, M. Burge, K. Clarke, S. Pattison, M. Nikfarjam, R. Zielinski, F. Day, C.E. Chee, A. Nagrial, M. IJzerman, P. Gibbs, B. Lee
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:ESMO Real World Data and Digital Oncology
Subjects:
pancreatic cancer
neoadjuvant
borderline resectable
data registry
real-world data
Online Access:http://www.sciencedirect.com/science/article/pii/S294982012300022X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S294982012300022X

Similar Items